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ABSTRACT 
Reduced protein expression of the cardiac ryanodine receptor (RyR2) is thought to affect 
the susceptibility to stress-induced ventricular tachyarrhythmia (VT) and cardiac alternans, but 
direct evidence for the role of RyR2 protein expression in VT and cardiac alternans is lacking. 
Here we used a mouse model (crrm1) that expresses a reduced level of the RyR2 protein to 
determine the impact of reduced RyR2 protein expression on the susceptibility to VT, cardiac 
alternans, cardiac hypertrophy, and sudden death. Electrocardiography (ECG) analysis revealed 
that after the injection of relatively high doses of caffeine and epinephrine (agents commonly used 
for stress test), wildtype (WT) mice displayed long-lasting VTs, whereas, the crrm1 mutant mice 
exhibited no VTs at all, indicating that the crrm1 mutant mice are resistant to stress-induced VTs. 
Intact heart Ca2+ imaging and action potential (AP) recordings showed that the crrm1 mutant mice 
are more susceptible to fast-pacing induced Ca2+ alternans and AP duration alternans compared 
with WT mice. The crrm1 mutant mice also showed increased heart weight-to-body weight ratio 
and incidence of sudden death at young ages. Furthermore, the crrm1 mutant hearts displayed 
altered Ca2+ transients with increased time-to-peak and decay time (T50), increased ventricular wall 
thickness and ventricular cell area compared with WT hearts. These results indicate that reduced 
RyR2 protein expression suppresses stress-induced VTs, but enhances the susceptibility to cardiac 
alternans, hypertrophy, and sudden death.   
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INTRODUCTION 
Ryanodine receptor type 2 (RyR2) is the major Ca2+ release channel expressed in the 
sarcoplasmic reticulum (SR) of cardiac muscle cells. It plays an essential role in excitation-
contraction coupling by governing SR Ca2+ release, which causes muscle contraction [1]. Given its 
important role in cardiac function, dysfunction of RyR2 can lead to various cardiac disorders. 
Indeed, a large number of naturally occurring mutations in RyR2 have been associated with 
catecholaminergic polymorphic ventricular tachycardia (CPVT), atrial or ventricular fibrillation, 
hypertrophic or dilated cardiomyopathies, and sudden cardiac arrest [2, 3]. RyR2 dysfunction as a 
result of abnormal post-translational modifications have also been implicated in various cardiac 
conditions, such as heart failure [4-6]. Although the molecular mechanisms by which RyR2 
mutations and post-translational modifications cause diseases are not completely understood, it is 
generally believed that most of these RyR2 mutations or modifications alter channel activation or 
inactivation, leading to enhanced or suppressed RyR2 activity [2, 5-12]. 
Besides alterations in the activation or inactivation properties of the channel, changes in the 
protein expression of RyR2 have also been implicated in the pathogenesis of cardiac diseases [13-
16]. It has been shown that the level of RyR2 protein expression is significantly increased in 
patients with paroxysmal atrial fibrillation (AF) and in a mouse model of AF [17, 18]. These 
observations suggest that enhanced protein expression of RyR2 may be associated with an 
increased susceptibility to AF. On the other hand, ablating the expression of RyR2 by gene-
targeted knock-out (KO) resulted in embryonic lethality [19], while heart-specific, conditional KO 
of RyR2 led to cardiac hypertrophy and sudden death [20]. Reduced RyR2 protein expression has 
also been proposed to be involved in cardiac alternans. Wan et al [21] showed that endocardial 
myocytes, which express less RyR2 and SERCA2a proteins, are more susceptible to cardiac 
alternans than epicardial myocytes, which express higher levels of RyR2 and SERCA2a proteins. 
Furthermore, reduction in RyR2 protein expression may affect the susceptibility to stress-induced 
ventricular arrhythmias. Some CPVT-linked RyR2 mutations, such as the deletion of exon-3 and 
the point mutation G357S, were found to markedly reduce the expression of the RyR2 protein [22-
24]. Interestingly, the clinical phenotypes and severities of individuals carrying these mutations 
appear to be highly variable, some of them are even asymptomatic [23, 25-28]. These observations 
suggest that reduced RyR2 protein expression may contribute to the incomplete penetrance of 
CPVT phenotypes. However, it is important to note that despite their potential association, direct 
evidence for the link between reduced RyR2 protein expression and CPVT susceptibility or cardiac 
alternans has yet to be established. 
In the present study, we employed a mouse model [19] in which the protein expression of the 
wildtype RyR2 is substantially reduced to investigate the impact of reduced RyR2 protein 
expression on CPVT, cardiac alternans, cardiac hypertrophy, and sudden death. We demonstrated 
for the first time that reducing the level of the RyR2 protein protects against CPVT, but enhances 
the susceptibility to Ca2+ alternans and action-potential duration alternans. Reduced RyR2 protein 
expression also resulted in cardiac hypertrophy and sudden death, as reported previously [20]. Our 
data suggest that reducing the protein expression of RyR2 may represent an effective approach for 
suppressing CPVT. 
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EXPERIMENTAL PROCEDURES  
Animal studies  
All animal studies were approved by the Institutional Animal Care and Use Committees at 
the University of Calgary and were performed in accordance with US National Institutes of Health 
guidelines. The RyR2-targeted mutant mouse (crrm1) was generated as described previously [19]. 
Adult homozygous crrm1 mutant mice and wildtype (WT) littermates (8-10 weeks) in the 129-E 
mouse background (Charles River) were used for all experiments. Note that in the study by 
Takeshima et al [19], two RyR2 mutant mouse lines were generated: one is a RyR2-targeted 
mutant mouse called crrm1 and the other is a Cre-recombined RyR2 mutant mouse called crrm2. In 
the crrm1 mutant mice, a loxP sequence was inserted into the 5’-untranslation region in exon 1, and 
a cassette containing a loxP sequence, the green fluorescence protein (GFP) cDNA, and the 
neomycin resistance gene (Neo) was inserted into the first intron of the mouse ryr2 gene. In the 
crrm2 mutant mice, the DNA sequence between the two loxP sites has been removed using the Cre-
mediated recombination, resulting in the deletion of exon 1 and thus the RyR2 knockout (KO). 
Takeshima et al. used the crrm2 mutant mice to study the impact of RyR2 KO on the heart. In the 
present study, we used the crrm1 mutant mice without subjecting them to Cre-mediated 
recombination. 
 
Western blot analysis  
The crrm1 mutant and WT mouse hearts were frozen by a liquid N2-precooled Wollenberger 
clamp. The frozen heart tissues were ground to powder in the presence of liquid N2 and 
homogenated in the homogenizing buffer (30 mM KH2PO4, pH 7.0, 40 mM NaF, 5 mM EDTA, 
0.3 M Sucrose, 4 μmol/L Leupeptin, 1 mM Benzamidine, 100 μmol/L PMSF, 0.5 mM DTT) using 
a precooled Brinkmann Polytron PT 15 homogenizer. The cell homogenate (100 μl) was 
solubilized in a final 500 μl buffer containing 3% SDS and 50 mM Tris-HCl (pH 7.5) at room 
temperature for one hour and incubated at 55°C for 10 minutes before centrifugation to remove 
unsolubilized materials. The solubilized proteins from WT or the crrm1 mutant hearts were 
separated by 6%, 8% or 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and were 
transferred to nitrocellulose membranes at 100 V for 1.5 hours at 4°C in the presence of 0.01% 
SDS [29, 30]. The nitrocellulose membranes were then blocked for one hour with phosphate 
buffered saline (PBS: 137 mM NaCl, 8 mM Na2HPO4, 1.5 mM KH2PO4 and 2.7 mM KCl, pH 7.4) 
containing 0.5% Tween-20 and 5% skim milk powder. The membranes were incubated separately 
with the anti-RyR (34c, mouse), anti-Cav1.2 (rabbit), anti-SERCA (rabbit), anti-NCX (mouse), 
anti-CASQ2 (rabbit), or anti-β-actin (rabbit) antibodies (Thermo Fisher Scientific) to detect the 
expression level of major Ca2+ handling proteins. The membranes were washed three times with 
PBS containing 0.5% Tween-20 for 15 minutes before incubating with the corresponding 
secondary anti-IgG antibodies conjugated with horseradish peroxidase (1:20,000) (Thermo Fisher 
Scientific) for 30 minutes. The detection of the bound antibodies was enhanced by 
chemiluminescence kit from Pierce and visualized by ImageQuant LAS 4000 from GE Healthcare 
Life Sciences. 
 
Hematoxylin and eosin (H&E) staining  
Hearts from the crrm1 mutant mice and their WT littermates were isolated and washed with 
Krebs-Ringers-HEPES (KRH) buffer (125 mM NaCl, 12.5 mM KCl, 25 mM HEPES, pH 7.4, 6 
mM glucose, and 1.2 mM MgCl2) and fixed with 4% paraformaldehyde solution via retrograde 
Langendorf perfusion system. The fixed hearts were cut across the long axis to show the four 
chambers and then put into tissue cassettes. The dehydrating, clearing and paraffining were 
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performed using Leica ASP300S tissue processor. The paraffin embedded blocks were cut at 5μm 
thick and mounted onto slides, air-dried for 30 minutes at room temperature and were baked at 
37°C overnight. The paraffin sections were deparaffinized by xylene and rehydrated through 
ethanol and tap water before labeling with hematoxylin. Three minutes after stained with 
hematoxylin, the slides were rinsed in 1% acid alcohol (70%) several times to remove free 
hematoxylin and then were immersed in PBS for dark-blue color reaction product. Thereafter, 
washed with distilled water and then stained with Eosin for 3 minutes. The H&E stained slides 
were dehydrated in alcohol, cleared in xylene and mounted with coverslips. Photomicrographs 
were captured with a bright filed microscope (Olympus BX53).  
 
Electrocardiographic (ECG) recordings and induction of cardiac arrhythmias in 
anesthetized mice  
The crrm1 mutant and WT mice were lightly anesthetized with isoflurane vapor (0.5-1%) and 
95% O2 and placed on a heating pad (27°C). Two subcutaneous needle electrodes were inserted 
into the right upper limb and left lower abdomen for ECG recordings (BIOPAC MP System, 
Goleta, CA). The ECGs were continuously monitored under anesthesia until heart rate became 
stable. Baseline ECGs were recorded for 5-10 minutes before stimulation. For induction of 
ventricular arrhythmias, mutant mice and their WT littermates were subjected to intraperitoneal 
injection of epinephrine (1.6 mg/kg) and caffeine (120 mg/kg) (low dose), or were injected with 
3.0 mg/kg epinephrine and 150 mg/kg caffeine (high dose). ECGs were continuously recorded for 
30 minutes after the infusion of epinephrine and caffeine [31].  
 
Monophasic action potential (MAP) recordings in Langendorff-perfused hearts  
The crrm1 mutant and WT mice were sacrificed by cervical dislocation. Their hearts were 
cannulated to a Langendorff apparatus for maintaining coronary perfusion with oxygenated 
Tyrode's buffer (118 mM NaCl, 5.4 mM KCl, 25 mM NaHCO3, 1 mM MgCl2, 0.42 mM NaH2PO4, 
11.1 mM glucose, 10 mM taurine, 5 mM creatine, pH 7.4) containing 1.8 mM Ca2+ at 35°C. A 
monophasic action potential electrode was placed against the epicardial surface of the lower 
middle part of the left ventricle for epicardial MAP recording. Baseline MAP was recorded for 5-
10 minutes before pacing at the right atrium from 5 to10 Hz at 4-10 V for >20 seconds to induce 
APD alternans. The total length of the recording was 30 minutes. MAP signals were amplified by 
Gould amplifiers (models 13-G 4615-58, 13-4615-50 and 13-4615-71) and acquired at 2000 
Hz/channel using a Data Translation (DT 2821) analog and digital input-output board. Analysis of 
MAP signals was performed using Acknowledgment (BIOPAC MP System, Goleta, CA).  
 
Laser scanning confocal Ca2+ imaging of intact hearts  
The crrm1 mutant mice and WT littermates were sacrificed by cervical dislocation. Their 
hearts were cannulated to a Langendorff apparatus for maintaining coronary perfusion with 
oxygenated Ca2+ free Tyrode's buffer for 3-5 minutes and loaded with 4.4 μM Rhod-2 AM 
(Biotium, Inc. Hayward, CA) for about 45 minutes at 25°C [32, 33]. Extracellular Ca2+ was 
stepwise introduced to the heart from 0.25, 0.5, 1.0, to 1.8 mM in the presence of 5 μM blebbistatin 
(Toronto Research Chemicals, Toronto, ON) at 35°C throughout the experiment. The Langendorff-
perfused hearts were placed on a recording chamber mounted onto the Nikon A1R microscope for 
in situ confocal imaging (line-scan) of Ca2+ signals from epicardial ventricular myocytes. The pixel 
size of the resulting line-scan images ranged between 1.8 and 2 ms in the temporal dimension and 
between 0.1 to 0.4 microns in the spatial dimension. Ca2+ alternans was induced by rapid electrical 
stimulation of the hearts at increasing frequencies (5‐12 Hz, 6 V). Data analysis was performed 
using NikonA1R analysis system and Image J software.  
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Image and signal processing  
The following signal and image processing methods were implemented using MATLAB 
(The Mathworks Inc., Boston, MA) as described previously [34, 35]. Briefly, Line-scan 
fluorescence images were filtered using a median filter applied iteratively a number of times 
according to an estimation of the image noise variance. Noise variance was robustly estimated by 
means of a median absolute deviation of the image pixels. Identification of individual cells in the 
line-scan was performed by manually labeling the cell regions. Average fluorescence signals of 
individual cells in each line-scan were automatically obtained by spatial averaging of the pixels 
belonging to each marked cell. Average fluorescence signals of single cells were further filtered by 
applying a continuous wavelet transform of the signal with Gaussian wavelets of order 2. Zero-
crossing of the derivative of the resulting wavelet transform was used to accurately locate peaks 
and valleys in the fluorescence signals. Peaks were then classified as either stimulated or 
spontaneous using cross-correlation with the stimulation pulse train. Peak amplitudes were defined 
as the difference between the peak and the corresponding previous valley. For each cell, alternans 
ratio was measured as the ratio of the absolute value of the difference in amplitude between two 
consecutive peaks over the amplitude of the largest peak. The presence of alternans periods was 
established by requiring at least six consecutive stimulated peaks presenting an alternans ratio 
above 0.05. For each cell, alternans duration was defined as the cumulative elapsed time of 
alternans periods over the total duration of the line-scan. The average alternans duration was 
determined by averaging alternans durations of all cells in one scan area; and the average alternans 
ratio was determined by averaging alternans ratios of cells that displayed alternans in the same 
scan area.  
 
Echocardiography 
Echocardiographic analysis of the WT and crrm1 mutant mice was carried out using the 
Vevo 770 echocardiography system equipped with a 30 MHz transducer probe (Visual 
Sonics, Toronto, Canada) as described previously [36]. Mice (8-9 weeks old) were gently 
constrained on a heating pad (37 oC) and anesthetized with 1.5-2% isoflurane. Parameters, 
including the end systolic and diastolic diameters of the left chamber, interventricular septum 
and posterior wall thickness, left ventricular fractional shortening, and ejection fraction were 
analyzed for each mouse in a blinded manner involving the B-Mode and M-Mode 
measurements. All data were averaged from 10 cardiac cycles per mouse.  
 
Statistical Analysis  
All values shown are mean ± SEM unless indicated otherwise. To test for differences 
between groups, we used unpaired Student's t-test (2-tailed) or one-way ANOVA with post hoc 
test. A P value <0.05 was considered to be statistically significant. 
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RESULTS 
 
Modification of the ryr2 gene for gene-targeted knock-out markedly reduces the protein 
expression of RyR2 
During the process of generating the RyR2 knock-out mice, Takeshima et al [19] previously 
produced a targeted mutant mouse (crrm1), in which a loxP sequence was inserted into the 5’-
untranslation region, and a cassette containing a loxP sequence, the green fluorescence protein 
(GFP) cDNA, and the neomycin resistance gene (Neo) inserted into the first intron of the mouse 
ryr2 gene (Fig. 1A). Although these insertions in the intron sequences generally have minimal 
impact on gene organization and expression, surprisingly, we found that homozygous crrm1 mutant 
mice displayed markedly reduced expression of the RyR2 protein. Immunoblotting analyses of 
whole heart lysates revealed that the expression level of the RyR2 protein in the crrm1 mutant 
hearts was substantially reduced compared with that in the WT hearts (23.3 ± 4.5% vs WT, 
p<0.01) (Fig. 1B, C). On the other hand, there were no significant differences in the expression 
levels of other major Ca2+ handling proteins between the crrm1 mutant and WT hearts, including 
the L-type Ca2+ channel, Na+/Ca2+ exchanger, the sarco/endoplasmic reticulum Ca2+ ATPase 
(SERCA), and calsequestrin (CASQ2) (Fig. 1B, C). Therefore, the crrm1 mutant mice express a 
markedly reduced level of RyR2 protein, and represent a useful model for studying the impact of 
reduced RyR2 protein expression. 
 
Reducing RyR2 protein expression protects against stress-induced ventricular 
tachyarrhythmia 
It has been suggested that the level of RyR2 protein may play an important role in 
determining the susceptibility to catecholaminergic polymorphic ventricular tachycardia (CPVT) 
[22, 24, 37]. However, direct evidence for the role of RyR2 protein expression in CPVT is lacking. 
To this end, we took advantage of the crrm1 mouse model to assess the impact of reduced RyR2 
WT protein expression on stress-induced ventricular tachyarrhythmia (VT). We monitored the 
occurrence of VTs in WT and crrm1 mutant mice using electrocardiography (ECG) recordings 
before and after the injection of a mixture of caffeine (120 mg/kg) and epinephrine (1.6 mg/kg). 
This combination of pharmacological reagents has been widely used to trigger VTs in mouse 
models of CPVT [31, 33, 38-40]. Consistent with those reported previously, WT mice showed 
short-durations of VTs (5.7 ± 4.1%) over the 30-min period of ECG recordings after the injection 
of these triggers (Fig. 2A, E, F). Interestingly, not a single episode of VTs was detected in the 
crrm1 mutant mice under the same conditions (Fig. 2C, E, F). These observations raise the 
possibility that the crrm1 mutant mice may be protected against stress-induced VTs. To test this 
hypothesis, we repeated the stress tests in WT and crrm1 mutant mice using higher doses of 
caffeine (150 mg/kg) and epinephrine (3.0 mg/kg). As expected, high doses of caffeine and 
epinephrine induced severe polymorphic and bidirectional VTs in WT mice with an average VT 
duration of 46.3 ± 16.0% over the 30-min period of ECG recordings (Fig. 2B, E, F). Remarkably, 
the crrm1 mutant mice showed no VTs at all after the injection of high doses of caffeine and 
epinephrine (Fig. 2D, E, F). Thus, the crrm1 mutant mice are resistant to stress-induced VTs. Taken 
together, these observations indicate that reducing RyR2 WT protein expression can protect 
against stress-induced VTs in mice. 
 
Reducing RyR2 protein promotes Ca2+ alternans in intact hearts 
We have previously shown that inhibiting the luminal Ca2+ activation of RyR2 suppresses 
stress-induced VTs, but enhances Ca2+ alternans [35]. It is possible that reducing the expression of 
the RyR2 protein, which suppresses stress-induced VTs, may also affect Ca2+ alternans. To test 
this possibility, we assessed the intracellular Ca2+ dynamics in intact working WT and the crrm1 
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mutant hearts stimulated at increasing frequencies (5-10 Hz) using in situ confocal laser scanning 
Ca2+ imaging. Figure 3 shows representative images and traces of Ca2+ transients obtained from 
WT and the crrm1 mutant hearts stimulated at 7 Hz. At this stimulation frequency, little or no Ca2+ 
alternans was detected in the WT hearts (Fig. 3A), whereas, the crrm1 mutant hearts showed severe 
Ca2+ alternans (Fig. 3B). The average duration of Ca2+ alternans was 80.2 ± 4.6% in the crrm1 
mutant hearts versus 10.6 ± 3.0% in the WT hearts. The average alternans ratio was 57.3 ± 4.4% in 
the crrm1 mutant hearts versus 5.8 ± 1.7% in the WT hearts (Fig. 3C,D). Furthermore, the threshold 
stimulation frequency at which Ca2+ alternans occurred was lower in the crrm1 mutant hearts than 
in the WT hearts (Fig. 4). Ca2+ alternans was readily detected in the crrm1 mutant hearts at a 
stimulation frequency of 5 Hz, whereas, higher stimulation frequencies (8-10 Hz) were required to 
induce Ca2+ alternans in WT hearts (Fig. 4). Moreover, the crrm1 mutant hearts displayed 
significantly longer alternans durations and higher alternans ratios at 5-10 Hz compared with the 
WT hearts at the same stimulation frequencies (Fig. 4A,B). It should be noted that reducing RyR2 
protein expression also affected the properties of Ca2+ transients. The crrm1 mutant hearts showed 
significantly increased time-to-peak and decay time (T50), but similar amplitude of Ca
2+ transients 
compared to WT hearts (Fig. 5). Collectively, these observations indicate that reduced RyR2 
protein expression enhances the susceptibility to Ca2+ alternans.  
 
Reducing RyR2 protein enhances action potential duration alternans 
We next determined whether reduced RyR2 protein expression affects the propensity for 
action potential duration (APD) alternans. Monophasic action potential (MAP) was recorded in 
Langendorff-perfused WT and the crrm1 mutant hearts. The hearts were stimulated with increasing 
frequencies from 5 to 10 Hz to induce action potential duration alternans. As shown in Fig. 6, WT 
hearts showed little or no APD alternans at the stimulation frequency of 8 Hz (Fig. 6A), whereas, 
the crrm1 mutant hearts exhibited significant APD alternans at the same stimulation frequency (8 
Hz) (Fig. 6B). As the stimulation frequency increased from 5 to 10 Hz, the ratios of APD alternans 
increased in both the WT and the crrm1 mutant hearts (Fig. 6C). However, the APD alternans ratio 
in the crrm1 mutant hearts was significantly higher than that in the WT hearts at each stimulation 
frequency (between 6-10 Hz). For instance, at 8 Hz, the average APD alternans ratio was 2.6 ± 
0.9% in WT hearts and 19.5 ± 5.6% in the crrm1 mutant hearts (Fig. 6C). These results indicate that 
reduced RyR2 protein expression enhances the susceptibility to APD alternans. 
 
The crrm1 mutant mice display cardiac hypertrophy and sudden death 
Tissue-specific, conditional KO of RyR2 in the heart resulted in cardiac hypertrophy and 
sudden death [20]. To determine whether constitutively reducing RyR2 protein expression can lead 
to cardiac hypertrophy and sudden death, we assessed and compared the weights of the WT and 
crrm1 mutant hearts of the WT and crrm1 mutant mice. Hematoxylin and eosin (H&E) staining of 
paraformaldehyde fixed heart sections revealed increased thickness of the ventricular walls (Fig. 
7A) and ventricular cell area (Fig. 7B,C) in the crrm1 mutant hearts compared with those in WT 
hearts. Consistent with these observations, echocardiographic analyses also revealed increased 
ventricular wall thickness in the crrm1 mutant hearts compared with the WT hearts (Table 1). 
Furthermore, the crrm1 mutant mice showed a significant increase in the heart weight-to-body 
weight ratio compared with the WT mice (56.0 ± 2.8% in crrm1 vs 40.7 ± 2.6% in WT) (Fig. 7D). 
Similar to that observed with the conditional RyR2 KO mice [20], we also found that the crrm1 
mutant mice exhibited sudden death at young ages, starting at ~40 days (Fig. 8). On the other hand, 
no sudden death was observed with the WT mice (Fig. 8). Taken together, these results indicate 
that reducing RyR2 protein expression can lead to cardiac hypertrophy and increase the incidence 
of sudden death.   
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DISCUSSION 
Although reduced RyR2 protein expression is likely to occur under various cardiac 
conditions, the impact of reduced RyR2 protein level on cardiac function is not well understood. In 
the present study, we exploited a mutant mouse model with reduced RyR2 protein expression. We 
found that reducing the protein expression of RyR2 suppresses stress-induced VTs, but enhances 
Ca2+ alternans and APD alternans. In addition, reduced RyR2 protein expression led to cardiac 
hypertrophy and increased the susceptibility to sudden death. These findings provide novel insights 
into the role of RyR2 protein expression in VTs and cardiac alternans. 
A remarkable finding from the present study is that mice with reduced RyR2 WT protein 
expression are resistant to stress-induced VTs, suggesting that the level of RyR2 WT protein 
expression can affect the propensity for stress-induced VTs. It has been shown that the severity of 
CPVT phenotypes in individuals with the same RyR2 mutations (e.g. deletion of exon-3 or G357S) 
can differ substantially [23, 25-28]. Although the exact mechanism underlying the phenotypic 
variability in the same families or in individuals with the same mutations is unknown, our finding 
suggests that reduced RyR2 protein expression may be one of the many factors that determine the 
penetrance of CPVT. It is possible that some CPVT-linked RyR2 mutations alter not only the 
gating properties of RyR2, but also its protein expression, which would in turn affect the 
propensity for CPVT. In support of this view, we have previously shown that deletion of exon-3 
and the point mutation G357S markedly reduce the protein expression of RyR2, which may 
contribute to the incomplete penetrance of CPVT in individuals with these mutations [22-24]. 
Interestingly, Bongianino et al [37] recently employed RNA interference to specifically reduce the 
protein expression of the RyR2 mutant allele in a CPVT mouse model expressing the RyR2 
mutation R4496C. They found that allelic silencing of the RyR2 R4496C mutant expression is able 
to prevent CPVT in these mice. These observations suggest that reducing the expression of the 
RyR2 mutant protein represents a promising strategy for the treatment of CPVT. Our data would 
further suggest that reducing the expression level of the total RyR2 protein (both WT and mutant) 
may also be protective against CPVT. In this regard, it would be of great interest to determine 
whether individuals with nonsense or frame-shift RyR2 mutations that result in haploinsufficiency 
display reduced or enhanced susceptibility to CPVT. 
It is important to note that suppressed RyR2 activity has been shown to enhance cardiac 
alternans [35]. Furthermore, reduced RyR2 protein expression has been implicated in the genesis 
of cardiac alternans [21]. Consistent with these observations, we found that reducing the protein 
expression of RyR2 indeed increases the propensity for Ca2+ and AP-duration alternans. Hence, 
although reducing the level of RyR2 protein expression can suppress stress-induced VTs, it can 
also increase the propensity for Ca2+ and APD alternans, a well-known cause of re-entrant 
arrhythmias that can lead to ventricular fibrillation and sudden death. Therefore, reducing the 
protein expression of RyR2 has the beneficial effect of suppressing stress-induced VTs, but the 
adverse effect of promoting cardiac alternans. Since cardiac alternans usually occurs at fast heart 
rates, one may be able to minimize the adverse effect of reduced RyR2 protein expression on 
cardiac alternans by controlling the heart rate. It is also important to note that reduced RyR2 
protein expression also increases the risk of developing cardiac hypertrophy and sudden death 
[20]. Hence, a future challenge would be to fine tune the protein expression of RyR2, in addition to 
normalizing the activity of RyR2, in order to maximize its suppressing effect on stress-induced 
VTs, while minimize its adverse effect on cardiac alternans, hypertrophy, and sudden death.  
The exact mechanism by which reducing RyR2 expression protects against stress-induced 
ventricular tachyarrhythmias (VTs), but promotes Ca2+ and APD alternans is unknown. It has been 
shown that enhanced RyR2 function can increase the propensity for spontaneous SR Ca2+ release, 
which in turn can lead to delayed afterdepolarization, triggered activity, and VTs [2, 3]. On the 
other hand, depressed RyR2 function can prolong the refractoriness of SR Ca2+ release, which in 
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turn can increase the propensity for Ca2+ alternans [41-44]. Consistent with these observations, we 
have previously shown that a RyR2 mutation E4872Q that reduces the activity of RyR2 by 
suppressing Ca2+ activation of the channel and spontaneous SR Ca2+ release protects against stress-
induced VTs. On the other hand, the depressed E4872Q mutation prolongs the refractoriness of SR 
Ca2+ release and promotes Ca2+ alternans and APD alternans. It is likely that the rate of SR Ca2+ 
release would depend on the level of the RyR2 protein, such that reducing RyR2 protein 
expression to some extent may mimic the depression or reduction in RyR2 function. In line with 
this view, we found that reducing RyR2 protein expression indeed decreases the rate of rise of Ca2+ 
transients. Hence, it is possible that like the depressed RyR2 mutant E4872Q, reducing RyR2 
protein expression may suppress spontaneous SR Ca2+ release and prolong SR Ca2+ release 
refractoriness. However, further investigations are needed to test these hypotheses. 
In summary, the present study demonstrates that reducing the protein expression of RyR2 
suppresses stress-induced VTs. This effect of reduced RyR2 protein expression on VTs may 
contribute to the incomplete penetrance of CPVT. Reduced RyR2 protein expression also increases 
the propensity for cardiac alternans, hypertrophy, and sudden death. Therefore, although moderate 
reduction in RyR2 protein expression may protect against CPVT, severe RyR2 protein reduction 
may lead to adverse effects.  
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CASQ2, Cardiac Calsequestrin  
11 
 
Table 1 
 
Table 1. Echocardiographic analyses of WT and crrm1 mutant mice 
 
                          WT crrm1 
LVS d (mm) 0.63±0.02 0.84±0.06** 
LVS s (mm) 0.93±0.04 1.20±0.05** 
LVPW d(mm) 0.73±0.06 0.84±0.05* 
LVPW s(mm) 0.93±0.03 1.19±0.03** 
FS (%) 31.63±2.81 25.79±3.6ns 
EF (%) 59.50±4.02 50.65±5.71ns 
Number of mice 10 6 
 
* p<0.05; ** p<0.01. Data shown are mean ± SEM. 
 
LVS d, interventricular septum thickness at end diastole; LVS s, interventricular septum 
thickness at end systole; LVPW d, left ventricular posterior wall thickness at end 
diastole; LVPW s, left ventricular posterior wall thickness at end systole; FS, fractional 
shortening. EF, ejection fraction. 
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FIGURES AND LEGENDS 
 
Fig.1 
 
 
 
 
Figure 1. The crrm1 mutant mice display reduced RyR2 protein expression.  
(A) Genetic manipulations in the mouse ryr2 gene are illustrated [19]. The loxP sequence 
was introduced into the BspEI site in exon 1 (Ex 1) and the loxP-GFP-Neo cassette was inserted 
into the ScaI site in intron 1 after exon 1. (B) Western blot analysis of RyR2, Cav1.2, NCX, 
SERCA2a, CASQ2, and β-actin expression in the crrm1 mutant and WT hearts. The same amount 
of heart lysate proteins was loaded in each lane, and the bands were detected using the 
corresponding antibodies (n = 3-4). (C) The expression level of each protein in the crrm1 mutant 
hearts was normalized to that of the WT hearts. Data shown are mean ± SEM (n=3-4) (** P < 
0.01). 
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Fig. 2 
 
 
 
Figure 2. The crrm1 mutant mice are resistant to stress-induced VTs. 
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ECGs were recorded in anesthetized RyR2 WT and the crrm1 mutant mice. The mice were 
injected (i.p.) with 120 mg/kg caffeine plus 1.6 mg/kg epinephrine (low dose) or 150 mg/kg 
caffeine plus 3.0 mg/kg epinephrine (high dose). ECGs were recorded for another 30 minutes after 
injection. Representative ECG traces of the RyR2 WT mice (A, B) and the crrm1 mutant mice (C, 
D) before and after injection of low dose (A, C) or high dose (B, D) of caffeine and epinephrine. 
The VT duration (%) in the RyR2 WT or the crrm1 mutant mice within each 3-min period (E) or 
within the 30-min period (F) of ECG recordings are shown. Data shown are mean ± SEM (n = 7 
for the low dose group, n = 5 for the high dose group) (*P < 0.05, **P < 0.01). 
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Fig.3 
 
 
 
 
Figure 3. Ca2+ alternans in intact WT and crrm1 mutant hearts paced at 7 Hz.  
Intact WT (A) and the crrm1 mutant (B) hearts were loaded with Rhod-2 AM and perfused 
with blebbistatin in a Langendorff setting. Ca2+ transients were elicited by pacing at 7 Hz and 
recorded using laser confocal imaging in the line-scanning mode. Cell boundaries were indicated 
by short bars on the left. The F/Fo traces depict the average fluorescence signal of the scan area. 
Alternans duration for each cell in the scan area and alternans ratio for each cell that displayed 
alternans in the same scan area were determined and averaged per cell to yield the average 
alternans duration (C) and average alternans ratio (D). Alternans duration is defined as the 
percentage of time in alternans over the 10s scanning period, and alternans ratio is defined as the 
20 
 
ratio of the difference in amplitude between the large and small Ca2+ transients over the amplitude 
of the large Ca2+ transient. Data shown are mean ± SEM (n = 14 scan areas from 6 WT hearts, n = 
20 scan areas from 7 crrm1 mutant hearts) (**p<0.01). 
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Fig. 4 
 
 
 
Figure 4. Average alternans duration and average alternans ratio at different pacing 
frequencies in intact WT and crrm1 mutant hearts.  
Intact WT and crrm1 mutant hearts were loaded with Rhod-2 AM and perfused with 
blebbistatin in a Langendorff setting. Ca2+ transients were elicited by pacing at different 
frequencies from 5 to 10 Hz, and recorded using laser confocal imaging in the line-scanning mode. 
(A) Average alternans duration (%) in cells in WT or the crrm1 mutant hearts over the 10s scanning 
period. (B) The average alternans ratio for cells that displayed alternans. Data shown are mean ± 
SEM (n = 14 scan areas from 6 RyR2 WT hearts, n = 20 scan areas from 7 crrm1 mutant hearts) 
(*p<0.05, **p<0.01). 
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Fig. 5 
 
 
 
Figure 5. Ca2+ transient properties of the WT and crrm1 mutant hearts 
Intact WT (A) and the crrm1 mutant (B) hearts were loaded with Rhod-2 AM and perfused 
with blebbistatin in a Langendorff setting. Ca2+ transients were elicited by pacing at 5 Hz and 
recorded using laser confocal imaging in the line-scanning mode. Cell boundaries were indicated 
by short bars on the left. The F/Fo traces depict the average fluorescence signal of the scan area. 
The average transient amplitude (C), time-to-peak (D), and decay time (T50) of Ca
2+ transients in 
the WT and crrm1 mutant hearts are indicated. Data shown are mean ± SEM (n = 4 scan areas from 
2 RyR2 WT hearts, n = 13 scan areas from 7 crrm1 mutant hearts) (**p<0.01). 
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Fig. 6 
 
 
 
Figure 6. The crrm1 mutant hearts are more susceptible to APD alternans.  
The WT and crrm1 mutant hearts were stimulated with increasing frequencies (5-10Hz) at 
5-10 V to induce APD alternans. Representative traces of MAP recordings from WT hearts (A) 
and the crrm1 mutant hearts (B) paced at 8 Hz are shown. (C) The APD alternans ratios of the WT 
and the crrm1 mutant hearts paced at different frequencies (5 - 10 Hz). Data shown are mean ± 
SEM (n = 6 for WT hearts, n = 4 for the crrm1 mutant hearts) (*p<0.05, **p<0.01). 
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Fig. 7  
 
 
 
 
Figure 7. The crrm1 mutant mice show cardiac hypertrophy 
(A) Representative sections of the WT and crrm1 mutant hearts stained with hematoxylin and 
eosin (H&E). (B) H&E stained and transversal sectioned myocardium from the free wall of the left 
ventricle. (C) The myocardium cell area in WT and crrm1 mutant hearts. (D) The heart- and body-
weight ratios of the WT and crrm1 mutant hearts. Data shown are mean ± SEM (n = 4 for WT, n = 
6 for crrm1 mutant mice) (** P < 0.01). 
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Figure 8 
 
 
 
 
Figure 8. The crrm1 mutant mice died suddenly at young ages.  
The survival rate of the crrm1 mutant mice (n=32) and the WT mice (n=22) is shown. Note 
that no WT mice died during the period (60 days) of observation, whereas, the crrm1 mutant mice 
started to die at the age of 40 days. 
 
 
 
 
